2.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACHV Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.75
Aprire:
$2.78
Volume 24 ore:
892.59K
Relative Volume:
1.17
Capitalizzazione di mercato:
$92.96M
Reddito:
-
Utile/perdita netta:
$-32.94M
Rapporto P/E:
-2.4144
EPS:
-1.11
Flusso di cassa netto:
$-24.95M
1 W Prestazione:
+15.52%
1M Prestazione:
-14.65%
6M Prestazione:
-13.27%
1 anno Prestazione:
-43.70%
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Nome
Achieve Life Sciences Inc
Settore
Industria
Telefono
425-686-1500
Indirizzo
22722 29TH DR. SE, SEATTLE, BC
Confronta ACHV con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ACHV
Achieve Life Sciences Inc
|
2.68 | 115.27M | 0 | -32.94M | -24.95M | -1.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
2024-09-27 | Iniziato | Raymond James | Strong Buy |
2023-05-10 | Reiterato | Maxim Group | Buy |
2021-06-23 | Iniziato | Oppenheimer | Outperform |
Achieve Life Sciences Inc Borsa (ACHV) Ultime notizie
Is Achieve Life Sciences Inc. a good long term investmentFree Stock Market Forecast Reports - Jammu Links News
Will Achieve Life Sciences Inc. stock split in the near futureFree Real-Time Market Predictions - Newser
What makes Achieve Life Sciences Inc. stock price move sharplyFree Discussion Group - Newser
Why Achieve Life Sciences Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
How Achieve Life Sciences Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Company’s Banking Shares: Up -49.72% from 52-Week Low, But Can the Momentum Hold? - investchronicle.com
Omnicom, Achieve Life Sciences Partner for AI-Driven Launch of New Nicotine Dependence Treatment - MSN
Achieve Life Sciences: The AI-Powered Push to Redefine Smoking Cessation - AInvest
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation - Seeking Alpha
Should You Hold Achieve Life Sciences (ACHV)? - Insider Monkey
ACHV: Achieve’s Busy Day - Yahoo Finance
Achieve Life Sciences (ACHV) Receives a Buy from Raymond James - The Globe and Mail
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
CSW INDUSTRIALS EVP, CFO Sell Shares at $284.18/Share on 2025-07-01. - AInvest
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities | ACHV Stock News - GuruFocus
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 3000 Index - MarketScreener
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 3000 Growth Index - MarketScreener
Achieve Life Sciences: Riding the Nicotine Cessation Wave, But Can It Overcome Regulatory Hurdles? - AInvest
Bothell biotech firm plans $45 million public offering to advance smoking cessation drug - The Business Journals
Tech And Biotech Stocks Take A Dive Following Surprising Announcements - Finimize
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Achieve Life Sciences (ACHV) Submits FDA Application for Smoking Cessation Drug | ACHV Stock News - GuruFocus
ACHV Gains Attention with Strategic Financial Moves | ACHV Stock News - GuruFocus
Achieve Life Sciences (ACHV) Launches $45 Million Stock Offering - GuruFocus
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation - The Manila Times
Achieve Life Sciences Announces Pricing of $45.0 Million Underwr - GuruFocus
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Achieve Life Sciences announces public offering to fund cytisinicline By Investing.com - Investing.com Canada
Achieve Life Sciences Announces Submission of NDA to FDA - GlobeNewswire
Breakthrough Smoking Cessation Drug Could Help 29M Americans: FDA Review Begins - Stock Titan
Achieve adds vapers to smokers in targeting multi-billion dollar market - The Pharma Letter
Bank of America Corp DE Purchases 9,760 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Institutional investors may adopt severe steps after Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) latest 15% drop adds to a year losses - simplywall.st
Owning 46% shares,institutional owners seem interested in Achieve Life Sciences, Inc. (NASDAQ:ACHV), - Yahoo
Squarepoint Ops LLC Buys Shares of 17,519 Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
achieve life sciences holds annual meeting with key votes By Investing.com - Investing.com India
Achieve Life Sciences Elects Board at Annual Meeting - TipRanks
achieve life sciences holds annual meeting with key votes - Investing.com
Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk (ACHV) - Seeking Alpha
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Late-Stage Smoking Cessation Drug Developer Achieve Life Sciences Sets Key Jefferies Conference Presentation - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Purchased by Northern Trust Corp - Defense World
Shay Capital LLC Sells 425,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
ACHV: New Insights from ORCA-3 Study to Be Shared at 2025 Conference | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present Phase 3 Study Findings on Cytisinicline for Smoking Cessation at 2025 ATS Conference - Nasdaq
Achieve Life Sciences Inc Azioni (ACHV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):